Steven Kliewer

Steven Kliewer is a Professor of Molecular Biology and Pharmacology at the University of Texas Southwestern Medical Center, holding the Diana K. and Richard C. Strauss Distinguished Chair in Developmental Biology. He is a member of the National Academy of Sciences. His research focuses on nuclear receptors and endocrine fibroblast growth factors (FGFs), particularly their roles in metabolism, bile acid homeostasis, and parasitic nematode biology. Kliewer collaborates with Dr. David Mangelsdorf in a joint laboratory investigating FGF21's effects on alcohol intoxication, energy regulation, and FGF19's role in bile acid metabolism. Their work also targets parasitic nematodes via nuclear receptor pathways, such as DAF-12 in Strongyloides stercoralis.

Education: BS in Biochemistry (Brown University, 1985), PhD in Molecular Biology (UCLA, 1990). Postdoctoral training at the Salk Institute (1990-1993), followed by roles at GlaxoSmithKline (1993-2002) as Director of Nuclear Receptor Research before joining UT Southwestern in 2002.

Research interests span metabolic regulation, FGF signaling, and drug development for parasitic infections. Key projects include FGF21's role in alcohol tolerance, FGF19's bile acid control, and leveraging nuclear receptors for antiparasitic therapies. Kliewer has contributed to over 100 publications since 2010, with recent work emphasizing FGF21's neuroendocrine effects and pancreatic secretagogue properties.

Awards: Member of the National Academy of Sciences (highlighting his contributions to metabolic endocrinology and parasitology).

Advising: Active mentorship in molecular biology and pharmacology, though specific advisee names are not listed in the provided texts.

Labs/Teams: Joint laboratory with David Mangelsdorf at UT Southwestern Medical Center, focusing on integrative studies of nuclear receptors and metabolic signaling pathways.